Fabio Lopez
Directeur/Bestuurslid bij Sellas Life Sciences Group Ltd.
Profiel
Fabio Lopez is currently a Director at Sellas Life Sciences Group Ltd.
He was previously a Director at SELLAS Life Sciences Group, Inc. from 2017 to 2018.
Actieve functies van Fabio Lopez
| Bedrijven | Functie | Begin |
|---|---|---|
Sellas Life Sciences Group Ltd.
 Sellas Life Sciences Group Ltd. Pharmaceuticals: MajorHealth Technology Sellas Life Sciences Group Ltd. manufactures pharmaceutical products. It focuses on innovative products to treat cancer and central nervous system diseases. The firm’s product candidate, licensed from Memorial Sloan-Kettering Cancer Center is a late-stage innovative WT1-targeting synthetic heteroclitic epitope immunotherapeutic in development for hematological malignancies and solid tumors characterized by an overexpression of the WT1 (Wilms Tumor Protein) antigen. The company was founded by Angelos M. Stergiou in 2012 and is headquartered in Zug, Switzerland. | Directeur/Bestuurslid | 29-12-2017 |
Eerdere bekende functies van Fabio Lopez
| Bedrijven | Functie | Einde |
|---|---|---|
| SELLAS LIFE SCIENCES GROUP, INC. | Directeur/Bestuurslid | 27-07-2018 |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| SELLAS LIFE SCIENCES GROUP, INC. | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Sellas Life Sciences Group Ltd.
Sellas Life Sciences Group Ltd. Pharmaceuticals: MajorHealth Technology Sellas Life Sciences Group Ltd. manufactures pharmaceutical products. It focuses on innovative products to treat cancer and central nervous system diseases. The firm’s product candidate, licensed from Memorial Sloan-Kettering Cancer Center is a late-stage innovative WT1-targeting synthetic heteroclitic epitope immunotherapeutic in development for hematological malignancies and solid tumors characterized by an overexpression of the WT1 (Wilms Tumor Protein) antigen. The company was founded by Angelos M. Stergiou in 2012 and is headquartered in Zug, Switzerland. | Health Technology |